APSR2026-932

Yes
Late-Breaking
Submitted
Poster Presentation
 
AP12-017
P94
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1241902-46904-APSR26_Poster rev3Oct26_429168.pdf
Format: PDF Only
16. Interstitial Lung Disease
9

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Su Ying Low * Singapore General Hospital Department of Respiratory and Critical Care Medicine Singapore Singapore
Yi Hern Tan - Singapore General Hospital Department of Respiratory and Critical Care Medicine Singapore Singapore
Li Wei Michelle Kam - Singapore General Hospital Department of Respiratory and Critical Care Medicine Singapore Singapore
May Zin Oo - Singapore General Hospital Department of Academic Clinical Program Singapore Singapore
Lee Wei Brian Chua - Singapore General Hospital Department of Respiratory and Critical Care Medicine Singapore Singapore
Valencia Lim - National University Hospital Division of Respiratory and Critical Care Medicine Singapore Singapore
Ziqin Ng - Tan Tock Seng Hospital Department of Respiratory and Critical Care Medicine Singapore Singapore
Gin Tsen Chai - Tan Tock Seng Hospital Department of Respiratory and Critical Care Medicine Singapore Singapore
Su Wei Felicia Teo - National University Hospital Division of Respiratory and Critical Care Medicine Singapore Singapore
 
 
 
 
 
 
Presenting Author Details
Su Ying
Low
low.su.ying@singhealth.com.sg
+6597427512
51-60
Singapore
Original Research
A prospective multi-centre study characterizing epidemiology and disease behaviour of Interstitial Lung Diseases in Singapore (ILD-Sing)
Maximum 25 words
Abstract Content
Background: Singapore, a South-East Asian multi-ethnic country, has limited epidemiological and clinical data on interstitial lung disease(ILD). Aim: Interim analysis from ILD-Sing registry to provide real-world view of our ILD patients.
Methods: 3 tertiary care university-affiliated hospitals with ILD units prospectively recruited patients into the ILD-Sing registry. Diagnosis was made through multidisciplinary discussions as per published guidelines. Data was analyzed using StataNow 19.5 Standard Edition.
Results: 474 patients were included from September 2022 to June 2025. Idiopathic pulmonary fibrosis(IPF) comprised 21%, connective tissue disease associated-ILD 53%, hypersensitivity pneumonitis 4%, unclassifiable 6% of ILD diagnosed. Further analysis was done for 203 patients(43% of cohort) recruited from 1 institution. Median duration of follow-up was 385days(range 214-1075days). Of the 149 non-IPF ILD patients, 20% showed progressive pulmonary fibrosis(PPF) as defined by ATS/ERS guidelines. IPF patients were older, more males, and 50% GAP stage 2. Non-IPF patients were younger, more females, and >50% GAP stage 1. 32% of IPF patients and 20% of non-IPF patients with PPF were on/ever on antifibrotics(AF) for median duration 511days(range 28-1322days) and 622days(range 31-1225days) respectively. AF was stopped in 22% of patients taking any AF drug due to adverse events. IPF and non-IPF with PPF showed a worse survival outcome compared to non-IPF without PPF (HR 3.07 95% CI 1.18-8.02, p=0.022, HR 5.97 95% CI 2.28-15.62, p<0.001 respectively). No survival benefit was seen in patients treated with AF.
Conclusion: This interim data analysis provides an overview of ILD subtypes seen in Singapore, with preliminary data on non-IPF patients with PPF, AF use, and clinical outcomes.
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
interstitial lung disease, real-world, registry
maximum 3 keywords and no abbreviations, separated by commas
The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE). The ILD-Sing registry was an independent, investigator-initiated study supported by Boehringer Ingelheim (BI). BI had no role in the design, analysis or interpretation of the results in this study; BI was given the opportunity to review the manuscript for medical and scientific accuracy.
277